L-Arginine

L-Arginine at a Glance

L-Arginine is a conditionally essential amino acid whose entire reputation rests on one reaction: it is the direct substrate for nitric-oxide synthase, the enzyme that makes nitric oxide — the body’s principal endogenous vasodilator. Feed the enzyme, the argument goes, and you get more blood flow.

The evidence is genuinely bimodal, and not in the direction the marketing suggests. The cardiovascular end — blood pressure, endothelial function — is the better-supported half. The sports-performance and “pump” claims that sell most of the powder are the weakest.

One fact explains much of that gap. Oral arginine is largely destroyed before it arrives: arginase in the gut and liver degrades a large fraction on first pass, so bioavailability is modest and varies a lot between people. L-citrulline sidesteps that loss entirely and raises plasma arginine more effectively than arginine does — which is why, for anything driven by nitric oxide, citrulline is often the better molecule to take.

What It’s Used For

• Blood pressure — the strongest signal, modest in size, plateauing around 9 g/day.
• Endothelial function — improves flow-mediated dilation, but mainly in people whose vascular function is already impaired.
• Preeclampsia in high-risk pregnancy — a supervised clinical use, not a self-directed one.
• Erectile dysfunction — mechanistically on target, but the positive data come mostly from combination formulas.
• Sickle cell disease pain — the one setting where arginine is genuinely depleted and repletion is physiologically justified.
• Exercise performance — the most-marketed use and the least supported.
• Perioperative immunonutrition — a real clinical benefit, but delivered inside a multi-ingredient surgical formula rather than as arginine alone.
• Glucose & insulin sensitivity — small trials in metabolically impaired groups; not a glucose-control supplement.
• Growth hormone — a genuine intravenous testing phenomenon that gets stretched into an oral muscle-building claim it cannot support.

Worth knowing what it is not for: in serious cardiovascular disease it has failed twice. Given after a heart attack it produced more deaths than placebo ^{14Reference 14Schulman SP et al. · 2006RCTL-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial — randomized controlled trialView study →}, and in peripheral arterial disease it showed no benefit and possible harm ^{15Reference 15Wilson AM et al. · 2007RCTL-arginine supplementation in peripheral arterial disease: no benefit and possible harm — randomized controlled trialView study →}. Those are the two hardest facts here — and they are worth stating precisely, because the early literature pointed the other way. A small 3-week study in 1998 reported large gains in pain-free walking distance in claudication ^{23Reference 23Böger RH et al. · 1998Clinical trialRestoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease — controlled trialView study →}, and that result is still quoted. It did not survive: the larger, longer, oral 6-month trial found the opposite ^{15Reference 15Wilson AM et al. · 2007RCTL-arginine supplementation in peripheral arterial disease: no benefit and possible harm — randomized controlled trialView study →}. When a short, small, infusion-era positive is overturned by a longer oral RCT, the later trial is the one to believe.

How It Works

Nitric-oxide synthase converts arginine to citrulline and NO. NO diffuses into vascular smooth muscle, relaxes it, and the vessel widens — which is the whole mechanism behind the blood-pressure, endothelial and erectile applications.

Two complications sit on top of that simple story. The first is the “arginine paradox”: plasma arginine is normally far above the concentration eNOS needs, so extra substrate should do nothing — yet it sometimes does. The leading explanation is competition with ADMA, an endogenous eNOS inhibitor, which is also why the benefit concentrates in people whose endothelium is already impaired rather than in healthy adults.

The second is first-pass loss. Gut and hepatic arginase, plus bacterial degradation, destroy much of an oral dose before it reaches circulation, and fractional absorption falls as the single dose rises — so a big bolus buys diarrhoea rather than plasma arginine.

Arginine also acutely stimulates growth-hormone release, which is the basis of the clinical arginine GH stimulation test. This is frequently repurposed as a marketing claim; in practice arginine blunts rather than aids the GH response to exercise ^{19Reference 19Kanaley JA · 2008ReviewGrowth hormone, arginine and exercise — reviewView study →}.

The full trial record is in Pharmacology & Research below.

Pharmacology & Research

L-Arginine is a conditionally essential amino acid whose main claim to fame is being the direct substrate for nitric-oxide synthase (NOS) — the enzyme that makes nitric oxide (NO), the body’s principal endogenous vasodilator. Its evidence base is genuinely bimodal: the cardiovascular/vascular literature (blood pressure, endothelial function) is the better-supported end, while the sports-performance and “pump” claims that sell most of the powder are the weakest. A recurring limiter runs through the whole record — oral arginine has modest and variable bioavailability because a large fraction is destroyed by arginase in the gut and liver before it reaches the circulation, which is why L-citrulline (which bypasses that first-pass loss and raises plasma arginine more effectively) is increasingly preferred for the same NO endpoints. Several of the clearer signals are also repletion effects, concentrated in people who start with impaired NO signalling (low baseline flow-mediated dilation, arginine-depleting disease, at-risk pregnancy) rather than a general boost in already-healthy adults.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume, then tempered for consistency, form/bioavailability, and how much of the effect depends on treating a deficiency rather than adding on top of adequacy. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Blood pressurePromising72%Two RCT meta-analyses; modest, consistent effect, dose-capped ~9 g/day ^{1,2Reference 1Shiraseb F et al. · 2022Meta-analysisEffect of l-Arginine supplementation on blood pressure in adults: a systematic review and dose-response meta-analysis of randomized clinical trials — meta-analysisView study →Reference 2Dong JY et al. · 2011Meta-analysisEffect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials — meta-analysisView study →}

02Endothelial functionPromising62%RCT meta-analyses of flow-mediated dilation; benefit concentrated where baseline is low ^{3,4Reference 3Bai Y et al. · 2009Meta-analysisIncrease in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low — meta-analysisView study →Reference 4Rodrigues-Krause J et al. · 2018Meta-analysisAssociation of l-Arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders — meta-analysisView study →}

03Preeclampsia in high-risk pregnancyPromising54%Systematic reviews/meta-analyses in at-risk pregnancies; heterogeneous, often arginine+citrulline ^{7,8Reference 7Naderipour F et al. · 2024Meta-analysisEfficacy of L-Arginine for preventing preeclampsia and improving maternal and neonatal outcomes in high-risk pregnancies — systematic review/meta-analysisView study →Reference 8Makama M et al. · 2025Meta-analysisL-Arginine and L-Citrulline for prevention and treatment of pre-eclampsia: a systematic review and meta-analysis — meta-analysisView study →}

04Erectile dysfunctionPromising48%Meta-analysis + network meta-analysis, but mostly combination formulas, not arginine alone ^{5,6Reference 5Rhim HC et al. · 2019Meta-analysisThe potential role of arginine supplements on erectile dysfunction: a systematic review and meta-analysis — meta-analysisView study →Reference 6Barbonetti A et al. · 2024Meta-analysisNutraceutical interventions for erectile dysfunction: a systematic review and network meta-analysis — network meta-analysisView study →}

05Sickle cell disease painShaky44%Phase-2 RCT + meta-analysis; a repletion effect specific to arginine-depleted patients ^{12,13Reference 12Morris CR et al. · 2025RCTArginine therapy for pain in sickle cell disease: a Phase-2 randomized, placebo-controlled trial — randomized controlled trialView study →Reference 13Sadeghi A et al. · 2023Meta-analysisEffects of l-arginine supplementation in patients with sickle cell disease: a systematic review and meta-analysis of clinical trials — systematic review/meta-analysisView study →}

06Perioperative immunonutritionPromising60%Meta-analysis of surgical trials, but arginine sits inside a multi-ingredient formula ^{20,21Reference 20Matsui R et al. · 2024Meta-analysisImpact of perioperative immunonutrition on postoperative outcomes in patients with upper gastrointestinal cancer — systematic review and meta-analysisView study →Reference 21Arribas-López E et al. · 2021Meta-analysisThe effect of amino acids on wound healing — systematic review and meta-analysis on arginine and glutamineView study →}

07Exercise performanceShaky28%One contested meta-analysis and a largely null endurance pooling ^{9,10,11Reference 9Viribay A et al. · 2020Meta-analysisEffects of arginine supplementation on athletic performance based on energy metabolism: a systematic review and meta-analysis — meta-analysisView study →Reference 10Trexler ET · 2025Meta-analysisCommon errors in sports nutrition meta-analyses lead to distortion of pooled effect estimatesView study →Reference 11d’Unienville NMA et al. · 2021Meta-analysisEffect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance — meta-analysisView study →}

08Glucose & insulin sensitivityShaky30%Mechanistic review plus one small 2025 trial, all in metabolically impaired groups ^{22,24Reference 22Hu S et al. · 2017ReviewL-arginine modulates glucose and lipid metabolism in obesity and diabetes — reviewView study →Reference 24Genazzani AD et al. · 2025Clinical trialImproved insulin sensitivity and reproductive profile in overweight and obese PCOS patients under L-arginine supplementation — clinical trial. https://pubmed.ncbi.nlm.nih.gov/39874141/View study →}

09Growth hormoneShaky22%Robust as an intravenous stimulation test; oral supplementation is not supported ^{19,25Reference 19Kanaley JA · 2008ReviewGrowth hormone, arginine and exercise — reviewView study →Reference 25Sodero G et al. · 2023ReviewGrowth hormone responses during arginine and clonidine stimulation testing — reviewView study →}

Mechanisms

Pharmacokinetics

Oral L-arginine is absorbed via intestinal cationic amino-acid transporters but suffers substantial first-pass metabolism: gut and hepatic arginase and bacterial degradation destroy a large fraction before it reaches systemic circulation, giving oral bioavailability commonly cited around ~20–50% and highly variable between people. Plasma half-life of the free amino acid is short (on the order of ~1–2 hours). A head-to-head pharmacokinetic study found oral L-citrulline raised plasma arginine more than L-arginine itself and increased NO metabolites, because citrulline escapes first-pass arginase and is converted to arginine in the kidney ^{16,17Reference 16Schwedhelm E et al. · 2008RCTPharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism — randomized controlled trialView study →Reference 17Bahadoran Z et al. · 2021ReviewEndogenous flux of nitric oxide: citrulline is preferred to arginine — reviewView study →}. Fractional absorption falls as the single dose rises and high boluses (≥9 g) commonly cause gastrointestinal upset — both reasons to split doses. Low “global arginine bioavailability” (the ratio of arginine to its catabolites) is itself a marker of cardiovascular risk ^{18Reference 18Tang WHW et al. · 2009ObservationalDiminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk — cohort/observationalView study →}. This PK picture is arguably the single most decision-relevant fact: for raising NO, citrulline is often the more effective molecule.

Clinical trials

L-arginine has an extensive registered-trial footprint spanning cardiovascular, obstetric, metabolic, haematologic and critical-care indications, though much recent activity uses arginine within combination products rather than as a sole agent, and there is limited fresh industry-funded monotherapy work (it is an off-patent commodity amino acid).

Last checked: August 2026.

Dietary Sources

Arginine is a non-essential/conditionally essential amino acid, so the body synthesises some (mainly via the intestinal–renal citrulline–arginine axis) and healthy adults obtain the rest from ordinary dietary protein. It is abundant in protein-dense foods, with the richest sources being nuts, seeds, legumes, poultry, seafood and dairy. Because it is a normal protein building block, outright dietary deficiency is rare in well-nourished people; the “conditionally essential” label reflects that requirements can outstrip synthesis during illness, trauma, rapid growth or specific diseases (such as sickle cell disease).

Food (per ~100 g)	Approx. arginine
Pumpkin/squash seeds	~5.4 g
Peanuts	~3.5 g
Soybeans (dry)	~2.6 g
Almonds	~2.5 g
Turkey / chicken breast	~1.8–2.0 g
Chickpeas / lentils (dry)	~1.8–2.0 g
Shrimp / tuna	~1.5–1.8 g

Amounts are indicative; refining and heavy processing of protein foods reduces content.

A typical mixed diet supplies roughly 4–6 g arginine/day — which overlaps the low end of the doses studied in blood-pressure trials. That overlap is part of why “extra on top of an adequate diet” so often shows only modest effects in replete adults.

Intake & Dosage

These are doses studied in research, not a personal recommendation.

There is no RDA/AI and no Tolerable Upper Intake Level for arginine — it is not treated as a dietary-essential nutrient. “No UL” means one has not been set, not that unlimited intake is safe.

• Blood pressure / vascular: most trials used 4–9 g/day oral L-arginine; the dose–response meta-analysis found benefit plateauing around 9 g/day, with no added effect — and more GI side effects — at higher intakes ^{1Reference 1Shiraseb F et al. · 2022Meta-analysisEffect of l-Arginine supplementation on blood pressure in adults: a systematic review and dose-response meta-analysis of randomized clinical trials — meta-analysisView study →}.
• Erectile dysfunction: the trials that report benefit generally used 1.5–5 g/day, usually inside a combination formula rather than as arginine alone ^{5,6Reference 5Rhim HC et al. · 2019Meta-analysisThe potential role of arginine supplements on erectile dysfunction: a systematic review and meta-analysis — meta-analysisView study →Reference 6Barbonetti A et al. · 2024Meta-analysisNutraceutical interventions for erectile dysfunction: a systematic review and network meta-analysis — network meta-analysisView study →}.
• Split the dose: oral bioavailability is modest and variable, and fractional absorption drops as the single dose rises, so the daily total is usually split into 2–3 doses. Single boluses of 9 g or more frequently cause diarrhoea and nausea.
• Consider citrulline instead: because L-citrulline bypasses first-pass arginase and raises plasma arginine more effectively, ~3–6 g/day of citrulline is often used to reach the same NO endpoint at lower GI cost ^{16,17Reference 16Schwedhelm E et al. · 2008RCTPharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism — randomized controlled trialView study →Reference 17Bahadoran Z et al. · 2021ReviewEndogenous flux of nitric oxide: citrulline is preferred to arginine — reviewView study →}.
• Watch the salt form: arginine is a free amino acid, so labelled grams are grams of L-arginine — but in arginine-HCl or arginine-AKG products a fraction of the weight is the counter-ion.

Safety

At studied oral doses L-arginine is generally well tolerated. The cautions that matter are not about toxicity — they are cardiovascular and pharmacological.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• Well tolerated at studied doses. GI upset is the dose-limiting effect, appearing mainly at single doses of 9 g or more.
• Avoid after a recent heart attack. The VINTAGE MI randomised trial found no benefit from adding L-arginine after acute MI and reported a higher death rate in the arginine group ^{14Reference 14Schulman SP et al. · 2006RCTL-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial — randomized controlled trialView study →}.
• No benefit, possible harm in peripheral arterial disease. A randomised trial found worse functional outcomes than placebo ^{15Reference 15Wilson AM et al. · 2007RCTL-arginine supplementation in peripheral arterial disease: no benefit and possible harm — randomized controlled trialView study →}.
• Additive hypotension. Arginine lowers blood pressure — combining it with antihypertensives, nitrates or PDE5 inhibitors (sildenafil, tadalafil) can stack.
• Renal or hepatic impairment. Arginine metabolism loads the urea cycle and kidneys.
• Clinician-directed use only in pregnancy. It has been studied for preeclampsia, but under supervision — see the box below.

Full Safety & Interactions Detail

Gastrointestinal upset — diarrhoea, nausea, bloating — is the dose-limiting adverse effect, and it appears mainly at single doses of 9 g or more. Splitting the daily total across 2–3 doses is the standard mitigation.

• The two cardiovascular failures are the important part of this section. In VINTAGE MI, L-arginine added to standard therapy after acute myocardial infarction produced no vascular benefit and a higher mortality rate than placebo ^{14Reference 14Schulman SP et al. · 2006RCTL-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial — randomized controlled trialView study →}. In peripheral arterial disease, a randomised trial found no benefit and possible harm on functional outcomes ^{15Reference 15Wilson AM et al. · 2007RCTL-arginine supplementation in peripheral arterial disease: no benefit and possible harm — randomized controlled trialView study →}. Both are the opposite of what the NO mechanism predicts, and both are reasons to keep arginine away from serious cardiovascular disease rather than toward it.
• Interactions: the main risk is additive hypotension with antihypertensive drugs, nitrates and PDE5 inhibitors. A comprehensive drug-interaction review has not been performed.
• Herpes (theoretical): arginine is a substrate for herpes-virus replication. The relevance to supplementation is unproven, but it is sometimes flagged for people with frequent cold sores — and it is the mirror image of the L-lysine claim.
• Renal or hepatic impairment: arginine metabolism loads the urea cycle and the kidneys, so caution applies where either is compromised.

Scope disclosure. Interactions were assessed partially — antihypertensives, nitrates, PDE5 inhibitors and the post-MI/PAD cardiovascular context were screened; a comprehensive review was not performed. Pregnancy and lactation were assessed only for the high-risk-pregnancy preeclampsia indication; general self-supplementation safety is not established. No Upper Limit exists, and absence of one does not mean unlimited intake is safe — GI tolerance and the ~9 g/day efficacy plateau are the practical ceilings in trials. Where something was not studied, it is marked “not assessed,” not “safe.”

Pregnancy & Lactation

• Caution in pregnancy• Caution while breastfeeding

Clinician-supervised use only — do not self-supplement. Arginine, often alongside citrulline or antioxidants, has been studied for preeclampsia prevention in high-risk pregnancies under medical supervision ^{7,8Reference 7Naderipour F et al. · 2024Meta-analysisEfficacy of L-Arginine for preventing preeclampsia and improving maternal and neonatal outcomes in high-risk pregnancies — systematic review/meta-analysisView study →Reference 8Makama M et al. · 2025Meta-analysisL-Arginine and L-Citrulline for prevention and treatment of pre-eclampsia: a systematic review and meta-analysis — meta-analysisView study →}. That is not the same as establishing that self-directed supplementation is safe in an ordinary pregnancy, which has not been done. Lactation safety at supplemental doses has not been evaluated. Any use in pregnancy should be directed and monitored by an obstetric clinician.

References

1. Shiraseb F, Asbaghi O, Bagheri R, et al. (2022). Effect of l-Arginine supplementation on blood pressure in adults: a systematic review and dose-response meta-analysis of randomized clinical trials — meta-analysis. Advances in Nutrition. https://pubmed.ncbi.nlm.nih.gov/34967840/
2. Dong JY, et al. (2011). Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials — meta-analysis. American Heart Journal. https://pubmed.ncbi.nlm.nih.gov/22137067/
3. Bai Y, et al. (2009). Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low — meta-analysis. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/19056561/
4. Rodrigues-Krause J, et al. (2018). Association of l-Arginine supplementation with markers of endothelial function in patients with cardiovascular or metabolic disorders — meta-analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/30577559/
5. Rhim HC, et al. (2019). The potential role of arginine supplements on erectile dysfunction: a systematic review and meta-analysis — meta-analysis. The Journal of Sexual Medicine. https://pubmed.ncbi.nlm.nih.gov/30770070/
6. Barbonetti A, Tienforti D, Antolini F, et al. (2024). Nutraceutical interventions for erectile dysfunction: a systematic review and network meta-analysis — network meta-analysis. The Journal of Sexual Medicine. https://pubmed.ncbi.nlm.nih.gov/39279185/
7. Naderipour F, Keshavarzi F, Mirfakhraee H, et al. (2024). Efficacy of L-Arginine for preventing preeclampsia and improving maternal and neonatal outcomes in high-risk pregnancies — systematic review/meta-analysis. International Journal of Fertility & Sterility. https://pubmed.ncbi.nlm.nih.gov/39564822/
8. Makama M, McDougall ARA, Cao J, et al. (2025). L-Arginine and L-Citrulline for prevention and treatment of pre-eclampsia: a systematic review and meta-analysis — meta-analysis. BJOG. https://pubmed.ncbi.nlm.nih.gov/39800868/
9. Viribay A, et al. (2020). Effects of arginine supplementation on athletic performance based on energy metabolism: a systematic review and meta-analysis — meta-analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/32370176/
10. Trexler ET (2025). Common errors in sports nutrition meta-analyses lead to distortion of pooled effect estimates. Comment on Viribay et al. — commentary. Nutrients. https://pubmed.ncbi.nlm.nih.gov/40733000/
11. d’Unienville NMA, Blake HT, Coates AM, et al. (2021). Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance — meta-analysis. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/34965876/
12. Morris CR, Hatabah D, Korman R, et al. (2025). Arginine therapy for pain in sickle cell disease: a Phase-2 randomized, placebo-controlled trial — randomized controlled trial. American Journal of Hematology. https://pubmed.ncbi.nlm.nih.gov/40270092/
13. Sadeghi A, Taherifard E, Dehdari Ebrahimi N, et al. (2023). Effects of l-arginine supplementation in patients with sickle cell disease: a systematic review and meta-analysis of clinical trials — systematic review/meta-analysis. Health Science Reports. https://pubmed.ncbi.nlm.nih.gov/37064309/
14. Schulman SP, et al. (2006). L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial — randomized controlled trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/16391217/
15. Wilson AM, et al. (2007). L-arginine supplementation in peripheral arterial disease: no benefit and possible harm — randomized controlled trial. Circulation. https://pubmed.ncbi.nlm.nih.gov/17592080/
16. Schwedhelm E, et al. (2008). Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism — randomized controlled trial. British Journal of Clinical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/17662090/
17. Bahadoran Z, Mirmiran P, Kashfi K, et al. (2021). Endogenous flux of nitric oxide: citrulline is preferred to arginine — review. Acta Physiologica. https://pubmed.ncbi.nlm.nih.gov/33089645/
18. Tang WHW, et al. (2009). Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk — cohort/observational. Journal of the American College of Cardiology. https://pubmed.ncbi.nlm.nih.gov/19477356/
19. Kanaley JA (2008). Growth hormone, arginine and exercise — review. Current Opinion in Clinical Nutrition and Metabolic Care. https://pubmed.ncbi.nlm.nih.gov/18090659/
20. Matsui R, et al. (2024). Impact of perioperative immunonutrition on postoperative outcomes in patients with upper gastrointestinal cancer — systematic review and meta-analysis. Nutrients. https://pubmed.ncbi.nlm.nih.gov/38474706/
21. Arribas-López E, et al. (2021). The effect of amino acids on wound healing — systematic review and meta-analysis on arginine and glutamine. Nutrients. https://pubmed.ncbi.nlm.nih.gov/34444657/
22. Hu S, et al. (2017). L-arginine modulates glucose and lipid metabolism in obesity and diabetes — review. Current Protein & Peptide Science. https://pubmed.ncbi.nlm.nih.gov/27356939/
23. Böger RH, Bode-Böger SM, Thiele W, et al. (1998). Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease — controlled trial. Journal of the American College of Cardiology. https://pubmed.ncbi.nlm.nih.gov/9809945/
24. Genazzani AD, Battipaglia C, Foschi M, et al. (2025). Improved insulin sensitivity and reproductive profile in overweight and obese PCOS patients under L-arginine supplementation — clinical trial. https://pubmed.ncbi.nlm.nih.gov/39874141/
25. Sodero G, Mariani F, Caprarelli M, et al. (2023). Growth hormone responses during arginine and clonidine stimulation testing — review. Growth Horm IGF Res. https://pubmed.ncbi.nlm.nih.gov/36502626/

View all 25 references▾